ViiV Healthcare A4001098

-
Investigator: Anne Luetkemeyer, MD
Sponsor: Pfizer

Visit project website

Location(s): United States

Description

Primary Outcome Measures:

  • Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities.